Enlicitide side effects to monitor in older adults

If your parent or spouse has just been prescribed enlicitide, the short answer is reassuring: in the available clinical trial data, enlicitide appears generally well tolerated. The longer, more useful answer is that caregivers should pay close attention to two side effects that can matter more at home than they look on a trial table: dizziness and diarrhea.

In CORALreef HeFH, dizziness was reported in 9% of people taking enlicitide compared with 4% taking placebo, and diarrhea was reported in 7% compared with 2% on placebo.[1] Those are not panic numbers. They are watch-the-bathroom-walk, watch-the-water-glass numbers. In an older adult, dizziness can turn into a fall. Diarrhea can turn into dehydration, weakness, lightheadedness, or confusion before anyone has had time to call it a “side effect.”

What enlicitide is, and why the safety discussion starts well

Enlicitide, approved as Lipfendra, is the first once-daily oral PCSK9 inhibitor approved by the U.S. Food and Drug Administration to reduce LDL-C in adults with hypercholesterolemia.[1] For families used to juggling injections, refill calendars, specialist notes, and pill boxes, “once daily” is not a small thing. A simple schedule can be the difference between a medication that works on paper and one that is actually taken.

The broader CORALreef Lipids safety picture is favorable. In a trial of 2,904 patients with a mean age of 63, adverse events occurred in 64.3% of people taking enlicitide and 62.1% of people taking placebo; serious adverse events occurred in 9.9% versus 12.0%; and discontinuation rates were 3.1% versus 4.1%.[2] Adherence to dosing instructions was reported at 97% over 52 weeks, which supports the practical appeal of a daily pill when a household is already managing several medicines.[2]

There is another useful point for older adults on complicated medication lists: enlicitide is not expected to have clinically relevant drug-drug interactions through cytochrome P450 metabolism.[3] That does not mean every medication question disappears; it does mean this is less likely to create the kind of CYP-mediated interaction tangle caregivers often worry about when a new prescription is added.

Cognitive safety is also reassuring in the currently available summaries. Enlicitide does not appear to negatively affect cognition, a point that matters when a family is already tracking memory changes, delirium risk, or dementia symptoms.[3] Still, cognition is not the first place most caregivers will notice a problem with this medication. The first signs are more likely to show up when someone stands, walks, eats, drinks, or goes to the bathroom.

The side effect to watch first: dizziness

Dizziness deserves first place because it has a direct path to injury. A younger adult may describe dizziness clearly and sit down quickly. An older adult may say they feel “off,” pause halfway down the hall, grip the counter a little longer, or stop wanting to take the stairs. Those clues count.

The moments that matter most are the ones that already challenge balance: getting up from a chair, standing after using the toilet, walking to the bathroom at night, stepping into the shower, turning quickly in the kitchen, or using stairs. If enlicitide-related dizziness occurs, those ordinary transitions are where a caregiver may see it before the older adult names it.

• Watch for new pauses before standing or walking.
• Notice whether they reach for walls, furniture, counters, or another person more often.
• Ask directly about spinning, lightheadedness, blurred vision, or feeling faint.
• Listen for softer signs: “I’m just tired,” “I don’t feel steady,” or “I’ll skip the shower today.”
• Treat any fall or near-fall after starting enlicitide as worth reporting to the prescribing clinician.

A fall does not have to happen for dizziness to matter. A near-fall, a sudden sit-down, a stumble caught on the counter, or a new refusal to walk without help may be the useful warning. The important pattern is change from baseline. If your parent already uses a cane but suddenly needs it inside the house, that is different from their usual routine. If they normally get up twice at night and now look unsteady on the second trip, that is useful information.

Do not stop enlicitide on your own because of mild dizziness unless the prescribing clinician has given that instruction in advance. Do make the dizziness concrete when you call: when it started, whether it happens after standing, whether blood pressure medicines or diuretics are also in the routine, whether there was a fall or near-fall, and whether the person is eating and drinking normally.

Diarrhea matters because dehydration can sneak up

Diarrhea was reported more often with enlicitide than with placebo in CORALreef HeFH: 7% versus 2%.[1] Again, that does not make enlicitide a drug to avoid. It does mean loose stools deserve a little structure, especially for someone who already drinks too little, takes a diuretic, has kidney concerns, or becomes weak quickly when meals are missed.

Older adults do not always feel thirst strongly or report stool changes promptly. Some are embarrassed. Some say “my stomach is off” and leave it there. Some skip lunch because they are worried about needing the bathroom again. By the time a caregiver notices weakness, dizziness, or confusion, the problem may no longer be only diarrhea; it may be fluid loss.

• Track how many loose stools occur in a day and whether that is a clear change from normal.
• Watch for reduced drinking, skipped meals, dry mouth, dark urine, unusual fatigue, or new lightheadedness.
• Be more cautious if they take a diuretic, have low usual fluid intake, or have been told to manage fluids carefully for another condition.
• Call the prescribing clinician if diarrhea persists, is accompanied by dizziness or weakness, or makes it hard to keep up with fluids.
• Seek urgent guidance for severe weakness, fainting, confusion, blood in stool, or signs of significant dehydration.

A simple notebook entry is often better than a vague message. “Three loose stools Tuesday, two Wednesday morning, drank about half usual fluids, dizzy when standing” gives the clinician something to work with. It also helps separate a one-day stomach upset from a pattern that began after the new medication.

A one-week monitoring plan after starting enlicitide

The first week is not the only time side effects can appear, but it is when families are most likely to catch a change if they are looking for it. The goal is not to hover. It is to notice the few things that would change the care plan.

This is also the right moment to update the household medication list. Add enlicitide, the dose, the start date, the prescribing clinician, and the reason it was prescribed. If the list is already messy, use a broader system such as a medication management guide for older adults so the new prescription does not become one more loose bottle on the counter.

What the current evidence can and cannot tell older adults

The strongest enlicitide-specific data available now are helpful, but they are not the same as a frail-older-adult safety study. CORALreef Lipids included 2,904 patients with a mean age of 63, so the trial included many people in older age ranges, but published age-stratified safety results for enlicitide by groups such as 65–74, 75–84, or 85 and older have not yet been released.[2]

Frailty is another gap. A geriatric review of PCSK9 inhibitor evidence noted that frailty was not assessed in PCSK9 inhibitor outcomes trials.[4] That matters because the person most vulnerable to a side effect is often not the average 63-year-old trial participant. It may be the 82-year-old who lives alone, uses a cane, takes a water pill, eats lightly, and is trying hard not to bother anyone.

There is class-level reassurance for PCSK9 inhibitors in older adults, but it should be kept in its lane. In the FOURIER trial, evolocumab showed efficacy across age quartiles up to age 85 without an increased relative risk of adverse events in older groups.[4] An ODYSSEY OUTCOMES age analysis found greater absolute risk reduction with alirocumab in patients older than 65.[5] Those findings support confidence in the PCSK9 inhibitor class, but they are not the same as enlicitide-specific geriatric outcomes data.

Enlicitide also does not yet have completed cardiovascular outcomes data of its own. The current discussion is built mainly on LDL-C lowering, safety, adherence, and tolerability data, while CORALreef Outcomes is ongoing.[2] For a family caregiver, that distinction does not change what to monitor this week, but it does keep the claims honest.

When to call the prescribing clinician

Call sooner rather than later if the side effect changes walking safety, hydration, or daily function. The call does not have to accuse the medication; it should connect the timing and the symptoms clearly enough for the clinician to decide what comes next.

• Persistent dizziness, especially when standing or walking
• Any fall, near-fall, fainting episode, or sudden new unsteadiness
• Diarrhea that continues, worsens, or interferes with eating or drinking
• Signs of dehydration, including unusual weakness, dry mouth, dark urine, confusion, or lightheadedness
• Any concern about how enlicitide fits with diuretics, blood pressure medicines, or a complex medication schedule

Keep the side-effect log short: date, dose taken, dizziness yes or no, loose stools, fluid intake concerns, falls or near-falls, and any missed doses. Bring that log to the next appointment or have it ready for a phone call. Enlicitide’s overall safety profile is encouraging, but older adults still deserve monitoring that matches real life: the chair, the hallway, the stairs, the bathroom, the water glass, and the person who notices when something has changed.

References

1. Merck’s LIPFENDRA™ (enlicitide) Is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia — Merck, July 16, 2026
2. FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol — AJMC
3. FDA Approves Lipfendra (enlicitide), the First Oral PCSK9 Inhibitor to Reduce LDL-C in Adults with Hypercholesterolemia — Drugs.com
4. Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents — Drugs & Aging, 2022
5. Effectiveness and Safety of Alirocumab in Older Patients in the Odyssey Outcomes Trial — Atherosclerosis, 2025